Open-label hydrocortisone

PreclinicalSmall molecule

SSiriraj Hospital

Open-label hydrocortisone is one of 22 small molecule programs targeting Sepsis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SepsisActive, not recruiting

SepsisPreclinical

Active, not recruiting

Competition

Competitive Landscape

308 competitors in Sepsis

#DrugCompanyPhaseTrials

Zyvox

Primaxin

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

3 4

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

2 5

Jardiance

Boehringer Ingelheim

Preclinical

1 6

Micardis

Boehringer Ingelheim

Preclinical

1 7

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

1 8

Levaquin

WWim Janssens

Preclinical

1 9

Pitocin

Nacl

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Sepsis

NCT06217939

Clinical

Trials by Indication[1]

Sepsis1 trial

Early Intravenous Hydrocortisone in Sepsis

Recruiting·SSiriraj Hospital·N/A·NCT06217939·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Open-label hydrocortisone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Open-label hydrocortisone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Open-label hydrocortisone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Siriraj Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSiriraj Hospital

Open-label hydrocortisone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Sepsis1 trial

References

Drug Info

Quick Facts

Related News